Skip to main
IGC

IGC Stock Forecast & Price Target

IGC Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

IGC Pharma Inc is positioned attractively in the market due to its focus on cannabinoid-based formulations targeting significant medical conditions, including Alzheimer's disease, which showcases a strong potential for therapeutic advancements. The investigational drug IGC-AD1 has exhibited promising preclinical results, specifically a clinically significant reduction in agitation among Alzheimer's patients, which may lead to further positive data and subsequent stock catalysts. Additionally, the company's current valuation appears favorable, supported by updated net present value analyses indicating substantial upside potential from the prevailing share price.

Bears say

IGC Pharma reported a net loss of $0.7 million, leading to an earnings per share (EPS) of $(0.01), which fell short of both the company's and the consensus estimates of $(0.02). The company anticipates revenue of $0.2 million, below the consensus estimate of $0.3 million, indicating potential challenges in generating adequate sales. Furthermore, the outlook is marred by numerous risks, including liquidity concerns, the uncertain efficacy and safety of product candidates in clinical trials, regulatory approval hurdles, and market competition, all of which could significantly hinder the company's financial performance.

IGC has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of India Globalization Capital and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About India Globalization Capital (IGC) Forecast

Analysts have given IGC a Strong Buy based on their latest research and market trends.

According to 1 analysts, IGC has a Strong Buy consensus rating as of Apr 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

India Globalization Capital (IGC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.